Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Abciximab

Abciximab

GP IIb/IIIa inhibitor (chimeric monoclonal Fab)

PCIIVAdult

Indication

High-risk PCI (use declining β€” institutional)

At a glance

INDICATIONS (CORE USE)

PCI adjunct β€” **bleeding** + **thrombocytopenia**; longer platelet-bound effect than small-molecule GPI.

ADULT DOSE (STANDARD)

Bolus **0.25 mg/kg** + infusion per cath lab protocol (verify vial)

MAX DOSE

Per institutional PCI maximum

Route

IV

PEDIATRIC DOSE

Not standard

Do not miss

Must-not-miss safety points

Major warning

- **Thrombocytopenia** - **Access site and systemic bleeding** with heparin - Hypersensitivity (chimeric protein)

Indications

USE IF: Selected PCI when cath lab protocol mandates GPI. AVOID IF: Active internal bleeding, stroke history, surgery <6 weeks per label context.

Primary

  • Adjunct to PCI for selected high-risk lesions (institution-dependent)

Dosing

STANDARD (ADULT PO)

Bolus + 12–24h infusion per PCI protocol

ADULT DOSE

Weight-based β€” pharmacy/cath lab double-check.

PEDIATRIC DOSE

N/A

MAX DOSE

Per protocol

Practical Note

Platelet count monitoring during and after infusion.

Warnings

Clinical warnings

  • **Major bleeding** (GI, ICH, post-procedural) β€” higher with **DAPT**, triple therapy, renal failure, age β€” counsel early symptoms
  • **Thrombocytopenia** on infusion β€” stop drug; **not** interchangeable monitoring vs oral agents
  • Thrombocytopenia
  • readministration hypersensitivity risk

Adverse effects

  • Bleeding
  • thrombocytopenia
  • hypotension

Contraindications

  • **Active major bleeding** β€” hold until controlled unless embedded in explicit procedural plan
  • **Recent major surgery / ICH** β€” generally **avoid** outside cath-lab ACS/PCI protocol
  • Active internal bleeding
  • recent surgery/trauma (context)
  • hypersensitivity

Drug interactions

  • **Heparin/bivalirudin stack in lab** β†’ bleed surveillance per protocol; **any new antiplatelet** β†’ **reassess** β€” not outpatient casual add-on
  • Heparin
  • other antiplatelets
  • fibrinolytics

Special populations

Pediatrics

Not standard

Pregnancy

Avoid unless lifesaving

Lactation

See lactation references and product labeling.

Renal impairment

No renal dose adjustment

Hepatic impairment

Use per PCI risk-benefit

Elderly

Bleed risk

Administration

IV in monitored setting only

Monitoring

  • Monitor: - **Platelet count falls on infusion** β†’ **stop GPI** + hematology - **Access-site or systemic bleed** β†’ **stop infusion** + hemostasis; **abciximab** longer platelet-bound effect than small molecules - **Hypotension with bolus** β†’ slow per protocol - **Transition to oral DAPT** per cath lab β€” **no duplicate** GPI + outpatient antiplatelet stack - Platelet count q4–6h during therapy typical protocol
  • Recheck: - New or worsening **bleeding**, unexplained **Hb drop**, or planned invasive procedure within **48–72h** β†’ reassess antiplatelet plan with cardiology/surgery when on DAPT - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)

Overdose / toxicity

Clinical Picture

**A) Therapeutic complication:** **bleeding** during/after PCI or **thrombocytopenia** on infusion β€” dominant scenarios. **B) True β€œoverdose”** beyond protocol bolus: management is **stop infusion + supportive/bleed care** β€” **no** specific reversal antidote (unlike salicylate toxicology).

Immediate Actions

**A:** Stop infusion β†’ ABCs; **platelet count**; access-site + systemic hemostasis; platelet transfusion if **severe thrombocytopenia + active bleed** per hematology. **B:** Supportive; prolonged monitoring if massive bolus error β€” institution-specific

Antidote

No specific antidote; treat complications (supportive care, platelets / hemostasis per protocol, anaphylaxis β†’ epinephrine per ACLS)

Decontamination

N/A

Escalation

Refractory bleed or platelets **<20k** with hemorrhage β†’ **ICU** + hematology; **short TΒ½** (eptifibatide/tirofiban) vs **abciximab** longer platelet-bound effect

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

**Platelet count** on drip. β†’ Longer platelet effect than eptifibatide.

Clinical pearls

Many centers have moved to oral P2Y12 loading β€” know your lab default. *Antiplatelet (all agents):* **Primary vs secondary (aspirin):** primary **not routine**; secondary **strong** when guideline-supported. **DAPT:** **do not stop early** post-stent without expert; duration **ACS vs stable CAD**; procedures need **explicit review**. **Bleeding-first:** GI/ICH/peri-op; **duplicate/hidden aspirin** on med rec. **Aspirin toxicity** (salicylate) is a **separate pathway** from antiplatelet bleed.

Antiplatelet safety

  • Platelet monitoring
  • Access site bleed
  • Heparin stack

Pharmacokinetics

Clears from plasma but platelet-bound effects persist longer than eptifibatide.

Mechanism of action

Blocks GP IIb/IIIa fibrinogen binding.

Common brand names

Saudi Arabia

ReoPro

Global

(placeholder β€” verify local product)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • DAPT duration and perioperative management follow **ESC/AHA/ACC** and local cardiology consensus β€” not one-size rules.
  • Primary prevention aspirin thresholds differ by guideline and age β€” verify regional primary-care policy.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • ACC / AHA / ESC cardiovascular guidelines (CAD, ACS, PCI)
  • FDA / SFDA product labeling
  • Local cath lab / antithrombotic protocol
  • ACC / AHA / ESC cardiovascular guidelines (CAD, ACS, PCI)
  • FDA / SFDA product labeling
  • Local cath lab / antithrombotic protocol

Do not miss

  • Document antiplatelet indication (primary vs secondary prevention vs stent DAPT)
  • Med reconciliation: OTC aspirin, NSAIDs, fish oil, anticoagulants
  • **Thrombocytopenia:** Acute drop on infusion β†’ **stop GPI** + hematology β€” can mimic HIT timing but pathway differs.
  • **Bleeding (access site / systemic / peri-PCI):** **Stop infusion** + hemostasis; **abciximab** longer platelet-bound effect than **eptifibatide/tirofiban** β€” procedural timing differs.
  • **Duplicate blockade:** GPI + DAPT + parenteral anticoagulant β†’ **maximal bleed** β€” protocol-driven only; **no casual addition** of NSAID/antiplatelet.
  • Platelets crash on abciximab β€” stop drug.
  • Platelet monitoring
  • Access site bleed
  • Heparin stack